



October 30, 2026

To,
Listing Operation Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001
(Scrip Code: 544644)

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Bandra (East), Mumbai-400051
(SYMBOL: CORONA)

Dear Sir / Madam,

Sub.: Outcome of the Board Meeting

Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we would like to inform that based on the recommendation of the Audit Committee, the Board at its meeting held today has, inter alia, approved the unaudited standalone and consolidated financial results along with limited review reports of the Company for the second quarter and half year ended on September 30, 2026. The said financial results are enclosed herewith.

In terms of Regulation 47 of the Listing Regulations, the Company will publish an advertisement for unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 2026.

The above results along with limited review reports are also being made available on the website of the Company at www.coronaremedies.com

A Press Release on financial results which is being submitted to the media, is also enclosed herewith.

The Board meeting commenced at 03:30 p.m. and concluded at 04:40 p.m.

You are requested to take note of the above.

Thanking you.

Yours faithfully,

For CORONA Remedies Limited

CHETNA

PRABHAT KUMAR

DHARAJIYA

Digitally signed by
CHETNA PRABHAT KUMAR
DHARAJIYA
Date: 2026.10.30 18:26:55
+05'30'

Chetna Dharajiya

Company Secretary and Compliance Officer

Encl.: A/a

Walker Chandio & Co LLP

Walker Chandio & Co LLP

Block No. D/15th Floor,
Cabin No. A8 to A10
"West Gate" Near YMCA Club,
S.G Highway, Sarkhej Road,
Ahmedabad-380015
Gujarat, India

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of CORONA Remedies Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of CORONA Remedies Limited (Formerly known as CORONA Remedies Private Limited) ('the Company') for the quarter ended 30 September 2026 and the year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Bhubaneswar, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Guwahati, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandio & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)(cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The review of standalone unaudited quarterly and year-to-date financial results for the period ended 30 September 2025 and audit of standalone financial results for the year ended 31 March 2026 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP who has expressed unmodified conclusion vide their review report dated 02 January 2026 and unmodified opinion vide their audit report dated 11 May 2026, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement.

Our conclusion is not modified in respect of this matter.

For Walker Chandio & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

M. Janani

Mehulkumar Sharadkumar Janani

Partner

Membership No. 118617

UDIN : 26118617HEJLGT5745



Place : Ahmedabad

Date : 30 October 2026

CORONA Remedies Limited

(formerly known as CORONA Remedies Private Limited)

Regd. Office: CORONA House,

C - Mondeal Business Park, Near Gurudwara, S.G.Highway,

Thaltej, Ahmedabad-380059, Gujarat, India

Tele.: +079-40233000 | Website : www.coronaremedies.com

CIN : L24231GJ2004PLC044656

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30 September 2026

(Amount Rs. in Crores except per share data)

Sr. No.	Particulars	For Quarter Ended			For Half Year Ended		For Year Ended
		30 September 2026 (Unaudited)	30 June 2026 (Unaudited)	30 September 2025 (Unaudited)	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)	31 March 2026 (Audited)
1	Income :						
	Revenue from operations	441.17	422.43	361.13	863.60	707.67	1,403.18
	Other income	2.48	3.15	2.27	5.63	4.29	10.65
	Total income	443.65	425.58	363.40	869.23	711.96	1,413.83
2	Expenses :						
	Cost of materials consumed	35.01	32.65	25.90	67.66	50.97	103.51
	Purchases of Stock-in-trade	68.24	57.20	28.11	125.44	62.88	150.38
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(22.74)	(12.33)	14.64	(35.07)	20.58	7.05
	Employee benefits expense	124.24	122.09	103.00	246.33	200.44	403.02
	Finance costs	2.75	2.69	1.93	5.44	3.92	6.97
	Depreciation and amortization expenses	15.06	13.24	9.20	28.30	18.12	37.87
	Other expenses	140.47	129.69	111.01	270.16	224.55	445.78
	Total expenses	363.03	345.23	293.79	708.26	581.46	1,154.58
3	Profit before exceptional item and tax (1-2)	80.62	80.35	69.61	160.97	130.50	259.25
4	Exceptional item :						
	Statutory impact of new Labour Codes (Refer note 4)	-	-	-	-	-	(19.10)
5	Profit before tax (3+4)	80.62	80.35	69.61	160.97	130.50	240.15
6	Tax expense :						
	Current tax	18.43	18.38	15.85	36.81	30.15	51.48
	Deferred tax	2.01	1.87	1.61	3.88	1.80	3.82
	Total Tax expense	20.44	20.25	17.46	40.69	31.95	55.30
7	Net Profit after tax for the period / year (5-6)	60.18	60.10	52.15	120.28	98.55	184.85
8	Other comprehensive income / (loss) for the period/year						
	Items that will not be reclassified to profit or loss						
	Remeasurement of net defined benefit plans	(0.96)	(0.40)	0.41	(1.36)	(0.67)	0.15
	Income tax effect on above	0.24	0.10	(0.10)	0.34	0.17	(0.04)
	Total other comprehensive income / (loss) for the period/year, net of tax	(0.72)	(0.30)	0.31	(1.02)	(0.50)	0.11
9	Total comprehensive income for the period/year (7+8)	59.46	59.80	52.46	119.26	98.05	184.96
10	Paid-up equity share capital (face value Rs.10/-)	61.16	61.16	61.16	61.16	61.16	61.16
11	Other Equity						684.81
12	Earnings per share (not annualised for the quarter and half year)						
	Basic (Rs.)	9.84	9.83	8.53	19.67	16.11	30.22
	Diluted (Rs.)	9.84	9.83	8.53	19.67	16.11	30.22



Unaudited Statement of Standalone Assets and Liabilities as at 30 September 2026

(Amount Rs. in Crores)

Particulars	As at 30 September 2026 (Unaudited)	As at 31 March 2026 (Audited)
A. ASSETS:		
1. Non-current assets		
a. Property, plant and equipment	425.23	291.14
b. Capital work-in-progress	21.83	143.12
c. Other intangible assets	246.94	262.83
d. Financial assets		
i. Investments	25.39	25.40
ii. Loans	-	0.01
iii. Other financial assets	50.86	129.87
e. Other non-current assets	1.77	3.57
Total non-current assets	772.02	855.94
2. Current assets		
a. Inventories	170.69	125.00
b. Financial assets		
i. Trade receivables	170.61	145.55
ii. Cash and cash equivalents	1.58	1.83
iii. Bank balances other than cash and cash equivalents	97.21	42.29
iv. Loans	0.11	0.26
v. Other financial assets	0.12	0.30
c. Other current assets	33.36	33.08
Total current assets	473.68	348.31
TOTAL ASSETS	1,245.70	1,204.25
B. EQUITY AND LIABILITIES:		
1. Equity		
a. Equity share capital	61.16	61.16
b. Other equity	742.91	684.81
Total equity	804.07	745.97
Liabilities		
2. Non-current liabilities		
a. Financial liabilities		
i. Borrowings	0.25	-
ii. Lease liabilities	17.29	18.88
b. Provisions	75.40	66.07
c. Deferred tax liabilities (net)	15.69	12.16
Total non-current liabilities	108.63	97.11
3. Current liabilities		
a. Financial liabilities		
i. Borrowings	94.28	142.86
ii. Lease liabilities	3.34	3.11
iii. Trade payables		
- total outstanding dues of micro enterprises and small enterprises	8.16	9.85
- total outstanding dues of creditors other than micro enterprise and small enterprise	107.50	80.48
iv. Other financial liabilities	63.99	76.46
b. Other current liabilities	8.38	6.99
c. Provisions	35.69	33.04
d. Current tax liabilities (net)	11.66	8.38
Total current liabilities	333.00	361.17
Total liabilities	441.63	458.28
TOTAL EQUITY AND LIABILITIES	1,245.70	1,204.25



Unaudited Statement of Standalone Cash Flows for the Half Year ended 30 September 2026

(Amount Rs. in Crores)

Particulars	For Half Year ended September 2026 (Unaudited)	For Half Year ended September 2025 (Unaudited)
Cash flow from operating activities		
Profit before tax	160.97	130.50
Adjustments for:		
Depreciation and amortization expenses	28.30	18.12
Finance costs	5.44	3.92
Interest income	(4.79)	(2.76)
Fair valuation adjustments of Investments designated as Fair Value through Profit & Loss (FVTPL)	0.01	(0.04)
(Gain) / loss on sale/disposal of fixed assets	(0.11)	0.43
Provision for expected credit loss	0.05	0.05
Provision for inventory obsolescence written back	(0.96)	(1.03)
Bad debts written off	0.01	0.05
Liabilities written back	-	(0.06)
Provision for expiry and breakage sales return	6.15	4.83
Net Unrealized exchange Gain	(0.25)	(0.24)
Operating profit before working capital changes	194.82	153.77
Changes in working capital		
Decrease/ (Increase) in inventories	(44.73)	23.22
Decrease/ (Increase) in trade receivables	(24.79)	(41.66)
Decrease / (Increase) in other current assets	(0.28)	5.58
Decrease / (Increase) in other financial assets	0.17	(8.51)
Decrease / (Increase) in non-current assets	(0.02)	0.04
Decrease in loans	0.16	0.21
(Decrease) / Increase in other financial liabilities	(10.17)	1.48
Increase in provisions	4.47	2.86
(Decrease) / Increase in trade payables	25.24	(3.24)
Increase in other current liabilities	1.39	2.29
Cash generated from operations	146.26	136.04
Income taxes paid (Net)	(33.53)	(22.60)
Net cash generated from operating activities (A)	112.73	113.44
Cash flow from Investing activities		
Payment for property, plant and equipment and intangible assets including capital work-in-progress, capital advance and creditors for capital goods	(26.33)	(32.51)
Proceeds from sale/ disposal of fixed assets	0.74	0.47
Fixed deposits placed / (matured)	24.10	(12.04)
Interest received	4.79	2.76
Net cash generated from / (used in) investing activities (B)	3.30	(41.32)
Cash flow from Financing activities		
Payment of dividend	(61.16)	(44.71)
Proceeds from long-term borrowings	0.25	-
Repayment of long-term borrowings	(16.00)	(18.00)
Repayment of short-term borrowings	(32.58)	(5.11)
Interest paid	(4.25)	(3.27)
Payment towards lease liability (excluding interest)	(1.52)	(1.37)
Interest on lease liability	(1.02)	(1.09)
Net cash (used in) financing activities (C)	(116.28)	(73.55)
Net (decrease) in cash and cash equivalents (A+B+C)	(0.25)	(1.43)
Effect of exchange differences on restatement of foreign currency Cash and cash equivalents*	0.00	0.01
Cash and cash equivalents at the beginning of the period	1.83	3.22
Cash and cash equivalents at the end of the period	1.58	1.80

*Effect of exchange differences on restatement of foreign currency Cash and cash equivalents for the half year ended 30 September 2026 represents amounting Rs.29,696/-

Particulars	For Half Year ended September 2026 (Unaudited)	For Half Year ended September 2025 (Unaudited)
Cash and cash equivalents comprise		
Balances with banks:		
In current accounts	0.09	0.30
Fixed deposits with maturity of less than 3 months	0.01	-
Cheques on hand	1.41	1.45
Cash on hand	0.07	0.05
Total cash and bank balances at end of the period	1.58	1.80



Notes to Standalone Financial Results for the Quarter and Half Year ended 30 September 2026 :

- 1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Initial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an issue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per equity share (other than employees) by selling shareholders. The total initial public offer expenses (except listing fees) are entirely allocated to the selling shareholders.
- 2 The above standalone unaudited financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 30 October 2026.
- 3 These standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ["Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.
- 4 On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the basis of the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact as "Statutory impact of new Labour Codes" under "Exceptional Items" amounting Rs.19.10 crores (Post tax Rs.14.29 crores) in the financial results for the year ended 31 March 2026.
The incremental impact consisting of gratuity of Rs.13.60 crores and long-term compensated absences of Rs.5.50 crores primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
- 5 The Company has only one reportable business segment namely - 'Pharmaceuticals' as determined by the Chief Operating Decision Maker in accordance with the Ind AS 108-"Operating Segment".
- 6 The figures for the corresponding previous periods have been regrouped/reclassified wherever necessary, to make them comparable.
- 7 As at 30 September 2026, the Company held fixed deposits aggregating to Rs. 146.82 Crores (comprising Rs. 49.68 Crores under other non-current financial assets, Rs. 0.01 Crores under cash and cash equivalents and Rs. 97.13 Crores under bank balances other than cash and cash equivalents), against which overdraft facilities amounting to Rs. 94.28 Crores were availed and disclosed under short-term borrowings.

For CORONA Remedies Limited,



Nirav K. Mehta
Managing Director & CEO
DIN : 01644041

Place: Ahmedabad
Date : 30 October 2026



Walker ChandioK & Co LLP

Block No. D/15th Floor,
Cabin No. A8 to A10
"West Gate" Near YMCA Club,
S.G Highway, Sarkhej Road,
Ahmedabad-380015
Gujarat, India

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of CORONA Remedies Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited) ('the Holding Company') and its associate (refer Annexure 1 for the list of associate included in the Statement) for the quarter ended 30 September 2026 and the consolidated year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Bhubaneswar, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Guwahati, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker ChandioK & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditor referred to in paragraph 5, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement also includes the Holding Company's share of net profit after tax of ₹ 0.13 crores and ₹ 0.14 crores and total comprehensive income of ₹ 0.01 crores and ₹ 0.01 crores, for the quarter and year-to-date period ended on 30 September 2026, respectively, as considered in the Statement, in respect of one (1) associate, whose financial results have not been reviewed by us. This financial results have been reviewed by other auditor whose review report has been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of this associate is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the report of the other auditor.

6. The review of unaudited consolidated quarterly and year-to-date financial results for the period ended 30 September 2025 and audit of consolidated financial results for the year ended 31 March 2026 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP who have expressed unmodified conclusion vide their review report dated 02 January 2026 and unmodified opinion vide their audit report dated 11 May 2026, respectively, whose report has been furnished to us by the management, and which has been relied upon by us for the purpose of our review of the Statement.

Our conclusion is not modified in respect of this matter.

For Walker Chandiook & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

M. Janani

Mehulkumar Sharadkumar Janani
Partner
Membership No. 118617
UDIN : 26118617UFJSEJ7230



Place : Ahmedabad
Date : 30 October 2026

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Bhubaneswar, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Guwahati, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

Annexure 1

List of the entities included in Statement

Sr. No	Entity Name	Relationship
1.	CORONA Remedies Limited	Holding Company
2.	La Chandra Pharma Lab Private Limited	Associate



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Bhubaneswar, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Guwahati, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandio & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

CORONA Remedies Limited

(formerly known as CORONA Remedies Private Limited)

Regd. Office: CORONA House,

C - Mondeal Business Park, Near Gurudwara, S.G.Highway,

Thaltej, Ahmedabad-380059, Gujarat, India

Tele.: +079-40233000 | Website : www.coronaremedies.com

CIN : L24231GJ2004PLC044656

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30 September 2026

(Amount Rs. in Crores except per share data)

Sr. No.	Particulars	For Quarter Ended			For Half Year Ended		For Year Ended
		30 September 2026 (Unaudited)	30 June 2026 (Unaudited)	30 September 2025 (Unaudited)	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)	31 March 2026 (Audited)
1	Income :						
	Revenue from operations	441.17	422.43	361.13	863.60	707.67	1,403.18
	Other income	2.48	3.15	2.27	5.63	4.29	10.65
	Total income	443.65	425.58	363.40	869.23	711.96	1,413.83
2	Expenses :						
	Cost of materials consumed	35.01	32.65	25.90	67.66	50.97	103.51
	Purchases of Stock-in-trade	68.24	57.20	28.11	125.44	62.88	150.38
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(22.74)	(12.33)	14.64	(35.07)	20.58	7.05
	Employee benefits expense	124.24	122.09	103.00	246.33	200.44	403.02
	Finance costs	2.75	2.69	1.93	5.44	3.92	6.97
	Depreciation and amortization expenses	15.06	13.24	9.20	28.30	18.12	37.87
	Other expenses	140.47	129.69	111.01	270.16	224.55	445.78
	Total expenses	363.03	345.23	293.79	708.26	581.46	1,154.58
3	Profit before Share of profit/(loss) of associate, exceptional item and tax (1-2)	80.62	80.35	69.61	160.97	130.50	259.25
4	Exceptional item :						
	Statutory impact of new Labour Codes (Refer note 4)	-	-	-	-	-	(19.10)
5	Share of profit/(loss) of associate (net of tax)	0.13	0.01	0.17	0.14	(0.03)	0.27
6	Profit before tax (3+4+5)	80.75	80.36	69.78	161.11	130.47	240.42
7	Tax expense :						
	Current tax	18.43	18.38	15.85	36.81	30.15	51.48
	Deferred tax	2.01	1.87	1.61	3.88	1.80	3.82
	Total Tax expense	20.44	20.25	17.46	40.69	31.95	55.30
8	Net Profit after tax for the period / year (6-7)	60.31	60.11	52.32	120.42	98.52	185.12
9	Other comprehensive income / (loss) for the period/year						
	Items that will not be reclassified to profit or loss						
	Remeasurement of net defined benefit plans	(0.96)	(0.40)	0.41	(1.36)	(0.67)	0.15
	Income tax effect on above	0.24	0.10	(0.10)	0.34	0.17	(0.04)
	Share of other comprehensive income / (loss) of associate (net of tax)	0.01	0.00	(0.00)	0.01	-	0.00
	Total other comprehensive income / (loss) for the period/year, net of tax	(0.71)	(0.30)	0.31	(1.01)	(0.50)	0.11
10	Total comprehensive income for the period/year (8+9)	59.60	59.81	52.63	119.41	98.02	185.23
11	Profit for the year/period attributable to:						
	Owners of the Company	60.31	60.11	52.32	120.42	98.52	185.12
		60.31	60.11	52.32	120.42	98.52	185.12
12	Other comprehensive income / (loss) for the period/year attributable to:						
	Owners of the Company	(0.71)	(0.30)	0.31	(1.01)	(0.50)	0.11
		(0.71)	(0.30)	0.31	(1.01)	(0.50)	0.11
13	Total comprehensive income for the period/year attributable to:						
	Owners of the Company	59.60	59.81	52.63	119.41	98.02	185.23
		59.60	59.81	52.63	119.41	98.02	185.23
14	Paid-up equity share capital (face value Rs.10/-)	61.16	61.16	61.16	61.16	61.16	61.16
15	Other Equity						685.70
16	Earnings per share (not annualised for the quarter and half year)						
	Basic (Rs.)	9.86	9.83	8.55	19.69	16.11	30.27
	Diluted (Rs.)	9.86	9.83	8.55	19.69	16.11	30.27



Unaudited Statement of Consolidated Assets and Liabilities as at 30 September 2026

(Amount Rs. in Crores)

Particulars	As at 30 September 2026 (Unaudited)	As at 31 March 2026 (Audited)
A. ASSETS:		
1. Non-current assets		
a. Property, plant and equipment	425.23	291.14
b. Capital work-in-progress	21.83	143.12
c. Other intangible assets	246.94	262.83
d. Investments accounted using equity method	26.27	26.12
e. Financial assets		
i. Investments	0.16	0.17
ii. Loans	-	0.01
iii. Other financial assets	50.86	129.87
f. Other non-current assets	1.77	3.57
Total non-current assets	773.06	856.83
2. Current assets		
a. Inventories	170.69	125.00
b. Financial assets		
i. Trade receivables	170.61	145.55
ii. Cash and cash equivalents	1.58	1.83
iii. Bank balances other than cash and cash equivalents	97.21	42.29
iv. Loans	0.11	0.26
v. Other financial assets	0.12	0.30
c. Other current assets	33.36	33.08
Total current assets	473.68	348.31
TOTAL ASSETS	1,246.74	1,205.14
B. EQUITY AND LIABILITIES:		
1. Equity		
a. Equity share capital	61.16	61.16
b. Other equity	743.95	685.70
Total equity	805.11	746.86
Liabilities		
2. Non-current liabilities		
a. Financial liabilities		
i. Borrowings	0.25	-
ii. Lease liabilities	17.29	18.88
b. Provisions	75.40	66.07
c. Deferred tax liabilities (net)	15.69	12.16
Total non-current liabilities	108.63	97.11
3. Current liabilities		
a. Financial liabilities		
i. Borrowings	94.28	142.86
ii. Lease liabilities	3.34	3.11
iii. Trade payables		
- total outstanding dues of micro enterprises and small enterprises	8.16	9.85
- total outstanding dues of creditors other than micro enterprise and small enterprise	107.50	80.48
iv. Other financial liabilities	63.99	76.46
b. Other current liabilities	8.38	6.99
c. Provisions	35.69	33.04
d. Current tax liabilities (net)	11.66	8.38
Total current liabilities	333.00	361.17
Total liabilities	441.63	458.28
TOTAL EQUITY AND LIABILITIES	1,246.74	1,205.14



Unaudited Statement of Consolidated Cash Flows for the Half Year ended 30 September 2026

(Amount Rs. in Crores)

Particulars	For Half Year ended September 2026 (Unaudited)	For Half Year ended September 2025 (Unaudited)
Cash flow from operating activities		
Profit before tax	161.11	130.47
Adjustments for:		
Share of loss / (profit) from Associate	(0.14)	0.03
Depreciation and amortization expenses	28.30	18.12
Finance costs	5.44	3.92
Interest income	(4.79)	(2.76)
Fair valuation adjustments of Investments designated as Fair Value through Profit & Loss (FVTPL)	0.01	(0.04)
(Gain) / loss on sale/disposal of fixed assets	(0.11)	0.43
Provision for expected credit loss	0.05	0.05
Provision for inventory obsolescence written back	(0.96)	(1.03)
Bad debts written off	0.01	0.05
Liabilities written back	-	(0.06)
Provision for expiry and breakage sales return	6.15	4.83
Net Unrealized exchange Gain	(0.25)	(0.24)
Operating profit before working capital changes	194.82	153.77
Changes in working capital		
Decrease/ (Increase) in inventories	(44.73)	23.22
Decrease/ (Increase) in trade receivables	(24.79)	(41.66)
Decrease / (Increase) in other current assets	(0.28)	5.58
Decrease / (Increase) in other financial assets	0.17	(8.51)
Decrease / (Increase) in non-current assets	(0.02)	0.04
Decrease in loans	0.16	0.21
(Decrease) / Increase in other financial liabilities	(10.17)	1.48
Increase in provisions	4.47	2.86
(Decrease) / Increase in trade payables	25.24	(3.24)
Increase in other current liabilities	1.39	2.29
Cash generated from operations	146.26	136.04
Income taxes paid (Net)	(33.53)	(22.60)
Net cash generated from operating activities (A)	112.73	113.44
Cash flow from Investing activities		
Payment for property, plant and equipment and intangible assets including capital work-in-progress, capital advance and creditors for capital goods	(26.33)	(32.51)
Proceeds from sale/ disposal of fixed assets	0.74	0.47
Fixed deposits placed / (matured)	24.10	(12.04)
Interest received	4.79	2.76
Net cash generated from / (used in) investing activities (B)	3.30	(41.32)
Cash flow from Financing activities		
Payment of dividend	(61.16)	(44.71)
Proceeds from long-term borrowings	0.25	-
Repayment of long-term borrowings	(16.00)	(18.00)
Repayment of short-term borrowings	(32.58)	(5.11)
Interest paid	(4.25)	(3.27)
Payment towards lease liability (excluding interest)	(1.52)	(1.37)
Interest on lease liability	(1.02)	(1.09)
Net cash (used in) financing activities (C)	(116.28)	(73.55)
Net (decrease) in cash and cash equivalents (A+B+C)	(0.25)	(1.43)
Effect of exchange differences on restatement of foreign currency Cash and cash equivalents*	0.00	0.01
Cash and cash equivalents at the beginning of the period	1.83	3.22
Cash and cash equivalents at the end of the period	1.58	1.80

*Effect of exchange differences on restatement of foreign currency Cash and cash equivalents for the half year ended 30 September 2026 represents amounting Rs.29,696/-

Particulars	For Half Year ended September 2026 (Unaudited)	For Half Year ended September 2025 (Unaudited)
Cash and cash equivalents comprise		
Balances with banks:		
In current accounts	0.09	0.30
Fixed deposits with maturity of less than 3 months	0.01	-
Cheques on hand	1.41	1.45
Cash on hand	0.07	0.05
Total cash and bank balances at end of the period	1.58	1.80



Notes to Consolidated Financial Results for the Quarter and Half Year ended 30 September 2026 :

- 1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Initial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an issue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per equity share (other than employees) by selling shareholders. The total initial public offer expenses (except listing fees) are entirely allocated to the selling shareholders.
- 2 The above consolidated unaudited financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 30 October 2026.
- 3 These consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ["Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.
- 4 On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the basis of the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact as "Statutory impact of new Labour Codes" under "Exceptional Items" amounting Rs.19.10 crores (Post tax Rs.14.29 crores) in the financial results for the year ended 31 March 2026.
The incremental impact consisting of gratuity of Rs.13.60 crores and long-term compensated absences of Rs.5.50 crores primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
- 5 The Company has only one reportable business segment namely - 'Pharmaceuticals' as determined by the Chief Operating Decision Maker in accordance with the Ind AS 108-"Operating Segment".
- 6 The figures for the corresponding previous periods have been regrouped/reclassified wherever necessary, to make them comparable.
- 7 As at 30 September 2026, the Company held fixed deposits aggregating to Rs. 146.82 Crores (comprising Rs. 49.68 Crores under other non-current financial assets, Rs. 0.01 Crores under cash and cash equivalents and Rs. 97.13 Crores under bank balances other than cash and cash equivalents), against which overdraft facilities amounting to Rs. 94.28 Crores were availed and disclosed under short-term borrowings.

For CORONA Remedies Limited,



Nirav K. Mehta
Managing Director & CEO
DIN : 01644041

Place: Ahmedabad
Date : 30 October 2026



PRESS RELEASE

CORONA Remedies delivers highest ever Revenue with growth of 22% for Q2FY27 on Y-o-Y basis, 1.9x the IPM growth

Ahmedabad, October 30, 2026:

CORONA Remedies Limited, one of the fastest growing companies amongst Top 30 Indian pharmaceutical companies, has announced its unaudited financial result for quarter & half year ended September 30, 2026.

Financial Performance Snapshot:

Particulars (₹ in Cr)	Q2FY27	Q2FY26	Y-o-Y (%)	H1FY27	H1FY26	Y-o-Y (%)
Revenue from Operations	441.2	361.1	22.2%	863.6	707.7	22.0%
EBITDA	96.0	78.5	22.3%	189.1	148.2	27.5%
EBITDA Margin (%)	21.7%	21.7%	-	21.9%	20.9%	-
Profit After Tax*	60.3	52.3	15.3%	120.4	98.5	22.2%
PAT Margin* (%)	13.7%	14.5%	-	13.9%	13.9%	-

*PAT & PAT Margins were lower on account of higher depreciation & amortization charge for our newly commissioned facilities & acquisition of brands, from which revenue contribution are expected to build up over the coming quarters.

Key Business Highlights:

- **Outpacing IPM Growth¹:** CORONA continues to be one of the **fastest growing** companies among Top 30 companies of IPM as per MAT Sep'26¹. CORONA has outperformed market **by 1.9 times** for MAT Sep'26¹. CORONA is at **14th rank in its Covered Market** and at 26th rank in overall IPM.
- **Focus on brand building:** CORONA now has **4 brands exceeding ₹ 100 crores** in annual sales, including **1 brand crossing ₹ 200 crores** as per **MAT Sep'26¹**.
- **Operational excellence and disciplined execution:** Leveraging all growth drivers to outperform IPM. **Volume growth 2x** higher than IPM, **Pricing 1.5x** higher, and **New Introductions 2.4x** higher than IPM for MAT Sep'26¹.
- **Outperforming Chronic Business:** Chronic + Semi Chronic contribution stands at **71.2%** for Q2 FY27 against 67.7% in Q2 FY26, as per MAT Sep'26¹. Growth of Chronic + Semi Chronic is **~350 bps higher** than company growth.
- **ANVISA GMP Certification:** Company has received Good Manufacturing Practice (GMP) certification from Brazil's National Health Surveillance Agency (ANVISA) for its manufacturing facility at Bhayla, Ahmedabad, covering both Oral Solid Dosage (OSD) and Women's Hormone production lines. This milestone further strengthens CORONA's manufacturing excellence towards its philosophy of **'ONE WORLD ONE QUALITY'**

¹: Pharmatrac MAT Sep'26

Commenting on the results, **Mr. Nirav K. Mehta, Managing Director & CEO**, CORONA Remedies Limited, said:

“We are pleased to announce another quarter of strong, consistent growth. Revenue grew 22.2% year-on-year in Q2FY27 and 22% in H1FY27, ahead of our stated guidance. Our domestic business grew at 22.9%, well ahead of the Indian Pharmaceutical Market (IPM) growth of 12%, and our chronic portfolio grew at nearly twice the rate of its market segment.

This outperformance reflects our disciplined execution and consistent focus on our long-term strategy. We remain committed to strengthening our core therapies, building powerful brands, driving operational excellence and investing in capabilities that will support our future growth.

The Indian pharmaceutical industry is underpinned by strong structural demand drivers. Backed by our diversified portfolio, established brands, expanding market reach and experienced leadership team, we are well positioned to capitalise on these opportunities and sustain our growth momentum.”

About CORONA Remedies Limited

Founded in 2004, CORONA Remedies Limited is an India-focused pharmaceutical company engaged in the development, manufacturing, and marketing of products across key therapeutic areas, including Women's Healthcare, Cardio-Diabetes, Pain Management, and Urology.

The company has established a strong presence in the Indian pharmaceutical market through its focus on scientific expertise, brand building, manufacturing excellence, and quality-driven operations. Its manufacturing facilities and research capabilities support its commitment to delivering high-quality healthcare solutions.

Disclaimer: Certain statements contained in this document may be statements of future expectations and other forward-looking statements that are based on management's current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of CORONA Remedies Limited or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an offer or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

For further information please contact

Company	Investor Relations Advisors
CORONA Remedies Limited CIN No: L24231GJ2004PLC044656 Chetna Dharajiya – Company Secretary & Compliance Officer	Strategic Growth Advisors Pvt Ltd. CIN No: U74140MH2010PTC204285 Sagar Shroff / Tanay Shah Email id: sagar.shroff@sgapl.net / tanay.shah@sgapl.net Tel No: +91 98205 19303 / +91 98333 91899